Importantly, the quantification of the prostate cancer antigen 3 (PCA3) lncRNA in urine samples has been developed as a diagnostic test for prostate cancer [129], suggesting that lncRNAs may be applicable to the analysis of non-invasive liquid biopsies for the diagnosis of cancers, including breast cancer. This evidence concerns the gene PCA3 and prostate carcinoma.